Company intelligence / Profile preview
Sparrow Pharmaceuticals
- Ownership
- Private
- Development stage
- Other
01
Overview
Sparrow Pharmaceuticals is developing novel therapies that utilize HSD-1 inhibition to address unmet needs in endocrinology and rheumatology. Their lead program SPI-62/prednisolone is in Phase 2 for Polymyalgia Rheumatica. Another program, Clofutriben, targeting 11β-HSD1 for ACTH-Independent Macronodular Adrenal Hyperplasia has been discontinued.
- Therapeutic areas
- EndocrinologyRheumatology
- Modalities
- Small molecule drugs
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Beyond the preview
Go deeper on Sparrow Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Sparrow Pharmaceuticals.